Abstract TU120: MS#1072 Association of chronic kidney disease with COVID-19 disease severity in the Hispanics/Latinos: the HCHS/SOL study

C Carmen Mendoza (UNC Chapel Hill, Chapel Hill, North Carolina, United States) J Jianwen Cai J James Lash (University of Illinois Chicago, Chicago, Illinois, United States) A Ana Ricardo (University of Illinois Chicago, Chicago, Illinois, United States) E Eliseo Perez-Stable (NIH, Bethesda, Maryland, United States) H Holly Kramer (Loyola University, Maywood, IL, USA.) S Sylvia Rosas (Joslin Diabetes Center, Boston, Massachusetts, United States) E Eugenia Wong (UNC Chapel Hill, Chapel Hill, North Carolina, United States) K Krista Perreira (University of North Carolina School, Chapel Hill, North Carolina, United States) D David Hanna C Carmen Isasi (Albert Einstein College of Medicine, Bronx, New York, United States) M Martha Daviglus N Nora Franceschini (University of North Carolina, Chapel Hill, NC, USA.)

Abstract

Introduction: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality. Disparities in COVID-19 severity by Hispanic/Latino ethnicity and comorbidities are known, but differences within Hispanic/Latino populations with different chronic kidney disease (CKD) stages are not well-studied. Objective: Conduct longitudinal analysis of CKD with incident COVID-19 infection and related hospitalization or death in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Methods: CKD at HCHS/SOL Visit 2 (2014-2017) was defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 or urine albumin to creatinine ratio (ACR) ≥30 mg/g. CKD stages were defined as Stage 1) (G1) eGFR ≥90 and ACR ≥30, 2) (G2) eGFR 60-89 and ACR ≥30, 3) (G3) eGFR 30-59, 4) (G4) eGFR 15-29, and 5) (G5) eGFR ≤15. A composite COVID-19 outcome between 2020-2023 was defined as adjudicated COVID-19 infection, positive SARS-CoV-2 test, positive immunoglobulin G serology, or COVID-related hospitalization or death. Severe COVID-19 was defined as COVID-related hospitalization or death. Odds ratios (OR) were estimated from logistic regression accounting for age, sex, center, Hispanic background, diabetes, hypertension, cardiovascular disease, and the HCHS/SOL’s complex sampling design. Results: At Visit 2, the mean (standard error) age was 47.6 (0.3) years, and 46% were male. Out of 9673 Hispanic/Latinos, 1188 (12%) had prevalent CKD, including 52% G1, 21% G2, 22% G3, 3% G4, and 1% G5. Overall, 18.9% of those with CKD had evidence of COVID-19, compared to 25.0% of non-CKD participants (p = 0.001). Hispanic/Latinos with CKD had a greater percentage of severe COVID-19 (3.2% versus 2.0%; p=0.01). G1 and G5 had the highest percentage of COVID-19 (21.5%) and severe COVID-19 (6.0%), respectively. CKD was not associated with the composite COVID-19 variable (OR 0.80, 95% confidence interval (CI) 0.63, 1.02) or severe COVID-19 (OR 1.04, 95% CI 0.63, 1.72) in adjusted models. Conclusions: CKD was not associated with COVID-19 severity in Hispanics/Latinos, possibly due to older age and more healthcare utilization.

Article Details

Journal Circulation
Volume / Issue Vol. 153, Issue Suppl_1
Published March 24, 2026
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (13)

C

Carmen Mendoza

UNC Chapel Hill, Chapel Hill, North Carolina, United States

J

Jianwen Cai

J

James Lash

University of Illinois Chicago, Chicago, Illinois, United States

A

Ana Ricardo

University of Illinois Chicago, Chicago, Illinois, United States

E

Eliseo Perez-Stable

NIH, Bethesda, Maryland, United States

H

Holly Kramer

Loyola University, Maywood, IL, USA.

S

Sylvia Rosas

Joslin Diabetes Center, Boston, Massachusetts, United States

E

Eugenia Wong

UNC Chapel Hill, Chapel Hill, North Carolina, United States

K

Krista Perreira

University of North Carolina School, Chapel Hill, North Carolina, United States

D

David Hanna

C

Carmen Isasi

Albert Einstein College of Medicine, Bronx, New York, United States

M

Martha Daviglus

N

Nora Franceschini

University of North Carolina, Chapel Hill, NC, USA.